Clinical Trials Directory

Trials / Terminated

TerminatedNCT00119015

The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
102 (actual)
Sponsor
University of Chicago · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).

Detailed description

Clinicians frequently prescribe an oral H1 antihistamine for allergic rhinitis patients with residual symptoms after taking an intranasal steroid. Surprisingly, the only studies investigating this combination of drugs have failed to show added efficacy of the H1 receptor over the intranasal steroids alone. Adding montelukast, a leukotriene receptor antagonist, to an intranasal steroid has not been studied in a placebo controlled fashion. Wilson and colleagues, in an open study of patients with chronic rhinosinusitis, showed a benefit of adding montelukast. The investigators would like to recruit perennially allergic subjects and place them on fluticasone for 2 weeks. Those subjects with residual symptoms would then be randomized to receive either placebo or montelukast in addition to continuing the fluticasone for an additional 2 weeks. A positive study would support clinical practice and would serve as a preemptive strike against managed care plans that would not allow prescriptions for both drugs. Hypothesis: The addition of montelukast to treatment of a perennially allergic subject with an intranasal steroid is more effective at relieving symptoms than a placebo.

Conditions

Interventions

TypeNameDescription
DRUGPlacebo
DRUGMontelukast
DRUGFluticasone propionate

Timeline

Start date
2005-07-01
Primary completion
2008-06-01
Completion
2009-01-01
First posted
2005-07-12
Last updated
2014-02-28
Results posted
2013-05-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00119015. Inclusion in this directory is not an endorsement.